Fiduciary Alliance’s Royalty Pharma RPRX Stock Holding History

Fiduciary Alliance’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-101	Closed	-$3.1K	–	776
2023 Q2	$3.1K	Buy	+101	New	+$3.42K	﹤0.01%	752

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fiduciary Alliance's RPRX Position: Q3 2023 in Review

Fiduciary Alliance sold out of Royalty Pharma (RPRX) in Q3 2023, closing a stake of 101 shares — an estimated $3.1K sold.

Fiduciary Alliance first reported a position in RPRX in Q2 2023 and held it in 1 quarter. The position peaked at $3.1K in Q2 2023. 313 funds tracked by Wall St. Rank hold RPRX as of Q3 2023.

Fiduciary Alliance reported no remaining Royalty Pharma position as of Q3 2023 after selling out during the quarter.
Fiduciary Alliance sold 101 Royalty Pharma shares in Q3 2023, an estimated $3.1K.
Fiduciary Alliance first reported a position in Royalty Pharma in Q2 2023 and held it in 1 quarter.
Fiduciary Alliance's Royalty Pharma position peaked at $3.1K in Q2 2023.
313 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2023.

Based on Fiduciary Alliance's 13F filing for Q3 2023, filed 18 Oct 2023.